« Return to News | CROs/Service Providers

Sartorius opens German production facility for bioreactors

Friday, September 14, 2012 12:19 PM

Sartorius, the Germany-based international laboratory and process technology provider, has officially opened its new plant in Guxhagen, Germany, for the manufacture of bioreactors.

After approximately one year of construction and $23.5 million, the new building will now manufacture bioreactors and further production equipment for customers in the biopharmaceutical industry. Covering a total area of nearly 10,000 square feet, the new building complex provides space for a high-tech manufacturing hall and offices for 240 employees. The building owner is Robos GmbH, from which Sartorius has rented the premises in a long-term lease.

"The new plant enables us to substantially enhance our manufacturing processes and creates additional capacity for us in view of the rising demand for biopharmaceutical production equipment,” said Joachim Kreuzburg, CEO and executive board chairman, Sartorius. “As a result, we are optimally prepared for further expansion, especially for single-use bioreactors.”

Sartorius has moved all operations from its former bioreactor production facility in Melsungen, Germany, where it had reached maximum capacity limits.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.